SP004INHIBITION OF THE C5A RECEPTOR BY CCX168 MARKEDLY REDUCES THE THROMBOGENIC POTENTIAL OF SERUM FROM PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME — Sara Gastoldi (2015) | RDL Network
SP004INHIBITION OF THE C5A RECEPTOR BY CCX168 MARKEDLY REDUCES THE THROMBOGENIC POTENTIAL OF SERUM FROM PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.